|
 The company joins other Indian drugmakers Glenmark Pharmaceuticals
Ltd and Strides Pharma Science Ltd that are conducting trials in
India for potential drugs for COVID-19, which currently has no
approved treatment or vaccine.
Sun Pharma said
http://pdf.reuters.com/pdfnews/
pdfnews.asp?i=43059c3bf0e37541&u=
urn:newsml:reuters.com:
20200529:nBSE5stp4F the pancreatitis drug, nafamostat mesilate, has
been "identified as a potential candidate for COVID-19 patients by
scientists at University of Tokyo and Leibniz Institute for Primate
Research, Germany".
The company said it has initiated manufacturing of the active
pharmaceutical ingredient (API) and the finished product of the drug
using technology from its unit, Pola Pharma Japan.
[to top of second column] |
In April, the University of Tokyo announced plans for a trial of
nafamostat mesilate and camostat mesilate, a related drug, licensed
in Japan and South Korea to treat chronic pancreatitis.
Sun Pharma shares gained after the announcement, and closed up 3.3%
at 474.25 rupees. Shares in Indian drugmakers have been on a tear
this year, with the Nifty pharma index rising 21.5% so far.
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Anil
D'Silva and Shinjini Ganguli)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
